Target intelligence / Profile preview

THUMPD3 antisense RNA 1 (THUMPD3-AS1)

Target
THUMPD3-AS1
Molecular classification
Long non-coding RNA (lncRNA), Enhancer RNA (eRNA), Other
01

Overview

THUMPD3 antisense RNA 1 (THUMPD3-AS1, also known as SETD5-AS1) is a **long non-coding RNA (lncRNA)** located on chromosome 3 (3p25.3), transcribed antisense to the THUMPD3 and SETD5 loci[1][2]. It functions as an **enhancer RNA (eRNA)** and regulates gene expression, particularly in the context of cancer, where it has been shown to promote proliferation and migration of tumor cells such as those in hepatocellular carcinoma and ovarian cancer[2][3]. THUMPD3-AS1 can act as a molecular sponge (ceRNA), modulating cellular pathways like hypoxia and interacting with various molecular signals important in malignancy[6]. Although high expression correlates with poor prognosis in cancer, there is currently no evidence of approved or investigational drugs directly targeting THUMPD3-AS1 as a therapeutic intervention, and its main significance is as a biomarker and regulator of oncogenic pathways rather than as a classical drug target[3][6].

Other names
SETD5-AS1SETD5 antisense RNA 1
02

Mechanism of action

Not drug-targeted: Current data lack evidence for direct pharmacological targeting[3][6] Regulation of nearby and co-expressed genes by transcriptional modulation and RNA-network effects[3][6]

03

Biological functions

Regulation of gene expression (as a putative eRNA and lncRNA)[3]Promotion of cell proliferation and migration (notably in cancer cell lines)[3]Functions as a competing endogenous RNA (ceRNA) and molecular sponge for other RNAs[6]Involved in pathways like hypoxia and HIF-1 signaling[6]Potential to regulate transcription through enhancer-associated mechanisms[3]
04

Disease associations

Cancer (including hepatocellular carcinoma and ovarian cancer, where it acts as an oncogene)[2][3]Other (emerging evidence for involvement in tumorigenesis and poor cancer patient survival)[3]
05

Safety considerations

None reported (as this is neither a protein-coding gene nor a current drug target; safety concerns relate to manipulating lncRNAs in general, which can have broad off-target regulatory effects)[3][6]
06

Biomarkers

Potential *biomarker for cancer prognosis*, especially in hepatocellular carcinoma (HCC)[3]High expression associated with poor survival in tumor patients[3]

Beyond the preview

Go deeper on THUMPD3 antisense RNA 1 (THUMPD3-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on THUMPD3 antisense RNA 1 (THUMPD3-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call